PIER MARIA FORNASARI

PIER MARIA FORNASARI
2023-01-18

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis published in Jama Network

A review of 9 studies suggested that plasma therapy may work in a group of immunocompromised people During the first months of 2020, when the coronavirus was spreading around the world, it was not known what the routes of transmission were and what medications could be beneficial to treat COVID-19 . Among other options, it began to be postulated that the blood plasma

No Comments InCovid-19

PIER MARIA FORNASARI
2023-01-17

Evidence of haemorrhages in fetal brain tissue associated with the presence of SARS-CoV-2

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has found evidence of small haemorrhages in fetal brain tissue during the peak of COVID-19 cases in the UK. The research, published in Brain, found that the haemorrhages are linked to a reduction in blood vessel integrity. The cause of these

No Comments InCovid-19

PIER MARIA FORNASARI
2023-01-04

Cornell University study identifies four major subtypes of long COVID

The post-COVID syndrome known as long COVID has four major subtypes defined by different clusters of symptoms, according to a study led by researchers at Weill Cornell Medicine. The study, published Dec. 1 in Nature Medicine, was the largest of its kind to examine long COVID. The researchers, who represent clinicians and informaticists, used a machine-learning algorithm

No Comments InCovid-19

PIER MARIA FORNASARI
2023-01-04

Treating COVID in a Shifting Landscape

SARS-CoV-2 keeps changing. What does this mean for the treatment of COVID-19? As the world enters year four of the COVID-19 pandemic, scientists have amassed a great deal of knowledge about the biology and behavior of SARS-CoV-2 and about the clinical features of the disease that it causes. They have also developed an impressive arsenal

No Comments InCovid-19

PIER MARIA FORNASARI
2023-01-03

Middle-age high normal serum sodium as a risk factor for accelerated biological aging, chronic diseases, and premature mortality: good hydration linked to healthy aging

NIH findings may provide early clues about increased risks for advanced biological aging and premature death. Adults who stay well-hydrated appear to be healthier, develop fewer chronic conditions, such as heart and lung disease, and live longer than those who may not get sufficient fluids, according to a National Institutes of Health study published in eBioMedicine(link

No Comments InWELLNESS

PIER MARIA FORNASARI
2023-01-03

Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in moderate-severe COVID-19

A study by Imperial College London, in the United Kingdom, shows an irregular activity of monocytes with a prothrombotic effect Among the complications most attributed to Covid-19 is thrombosis. The formation of blood clots in the veins or arteries in the weeks following the coronavirus infection , impairing blood circulation, was one of the symptoms seen frequently among patients around

No Comments InCovid-19

PIER MARIA FORNASARI
2023-01-03

In Shanghai, up to 70% 25 million population may have been infected with COVID-19

A senior doctor at one of Shanghai’s top hospitals says 70 per cent of the megacity’s population may have already been infected with COVID-19 during China’s huge surge in cases, state media are reporting. Key points: The steep rise in infections came after years of hardline restrictions were abruptly loosened last month, with little warning or

No Comments InCovid-19

PIER MARIA FORNASARI
2023-01-03

NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration (FDA)(link is external) for the treatment of adults and

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2023-01-01

What we know about Omicron XBB.1.5 the new Dominant Covid-19 subvariant in U.S and UK.

Now the U.S. is dealing with a new X-factor. Actually, it’s an XBB-factor: the XBB.1.5 Omicron subvariant. The XBB.1.5 comprised an estimated 40.5% of all Covid-19 cases over this past week, based on data from the Centers for Disease Control and Prevention (CDC). That’s up from 21.7% the week prior. That one week jump has vaulted

No Comments InCovid-19

PIER MARIA FORNASARI
2022-12-31

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial with a 99% response rate

An innovative immunotherapy combination has shown a stunning 99% response rate in children with relapsed leukemia. The phase 2 trial, run jointly between researchers at St. Jude Children’s Research Hospital in Memphis and Shanghai Children’s Hospital in China tested the therapy in 225 children who had relapsed after conventional treatment. The work published in the Journal

No Comments InCAR-T

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

All posts by PIER MARIA FORNASARI

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis published in Jama Network

Evidence of haemorrhages in fetal brain tissue associated with the presence of SARS-CoV-2

Cornell University study identifies four major subtypes of long COVID

Treating COVID in a Shifting Landscape

Middle-age high normal serum sodium as a risk factor for accelerated biological aging, chronic diseases, and premature mortality: good hydration linked to healthy aging

Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in moderate-severe COVID-19

In Shanghai, up to 70% 25 million population may have been infected with COVID-19

NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

What we know about Omicron XBB.1.5 the new Dominant Covid-19 subvariant in U.S and UK.

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial with a 99% response rate